



Keenan Pharmacy Services
San Joaquin Valley Insurance Authority
Quarterly Key Pharmacy Benefit Metrics
Data Reviewed Through: 4th Quarter

Presented by Alexandria Van Brunt
Sr. Account Manager, KPS

Quarterly Key Pharmacy Benefit Metrics

Executive Summary

- Q4 2020 Highlights:
 - SJVIA's total plan cost increased slightly from \$4,761,468 in Q3 to \$4,769,527 in Q4.
 - Tulare: \$1,954,639 in Plan Cost
 - Fresno: \$2,814,888 in Plan Cost
 - Majority of the SJVIA members continue to fill scripts at retail.
 - Retail scripts account for 98.66% of plan spend.
 - Q4 specialty spend Increased about 2%
 - Specialty Plan Costs in Q4: \$1,559,440 (32.7% of plan spend)
 - Specialty claims volume increased in Q4.
 - SJVIA specialty plan costs continue to trend slightly below the national average range.
 - Top Five Clinical Cost Drivers (Q1-Q4 2020):
 - HUMIRA PEN (ANALGESICS - ANTI-INFLAMMATORY)
 - 2020 (Q1-Q4) ingredient costs: \$928,313.24
 - TRULICITY (ANTIDIABETICS)
 - 2020 (Q1-Q4) ingredient costs: \$721,785.44
 - JANUVIA (ANTIDIABETICS)
 - 2020 (Q1-Q4) ingredient costs: \$414,040.47
 - JARDIANCE (ANTIDIABETICS)
 - 2020 (Q1-Q4) ingredient costs: \$368,209.49
 - OZEMPIC (ANTIDIABETICS)
 - 2020 (Q1-Q4) ingredient costs: \$360,334.00

Quarterly Key Pharmacy Benefit Metrics

Cost Trend by Quarter

Category	Q1 2019	Q2 2019	Q3 2019	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020
Gross Cost	\$4,900,708	\$4,904,091	\$4,794,964	\$4,844,157	\$5,320,273	\$5,153,562	\$5,145,875	\$5,150,035
Plan Cost	\$4,499,486	\$4,530,265	\$4,428,298	\$4,472,131	\$4,893,192	\$4,763,678	\$4,761,468	\$4,769,527
Member Cost	\$401,222	\$373,825	\$366,666	\$372,026	\$427,081	\$389,883	\$384,407	\$380,507




- This report details the total member and plan costs, by quarter, for the most recent 8 quarter period
- Gross cost = plan cost + member cost

Quarterly Key Pharmacy Benefit Metrics

Plan Cost by Channel


Category	Q1 2019	Q2 2019	Q3 2019	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020
Retail Brand	\$1,310,834	\$1,214,908	\$1,202,807	\$1,162,594	\$1,252,574	\$1,186,673	\$1,204,674	\$1,213,904
Retail Generic	\$621,808	\$554,337	\$550,879	\$671,424	\$767,794	\$675,196	\$661,165	\$568,630
Retail90 Brand	\$748,829	\$818,939	\$784,114	\$819,714	\$901,044	\$886,199	\$915,081	\$928,860
Retail90 Generic	\$408,135	\$374,568	\$378,526	\$356,074	\$397,208	\$405,162	\$458,566	\$455,767
Mail Brand	\$28,004	\$39,999	\$40,973	\$35,685	\$35,378	\$22,627	\$32,105	\$22,821
Mail Generic	\$21,682	\$20,150	\$16,982	\$15,576	\$14,795	\$15,814	\$18,672	\$20,104
Specialty	\$1,360,194	\$1,507,365	\$1,454,017	\$1,411,065	\$1,524,399	\$1,572,007	\$1,471,204	\$1,559,440



Quarterly Key Pharmacy Benefit Metrics

Total Claims Volume by Channel


Category	Q1 2019	Q2 2019	Q3 2019	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020
Retail Brand	3,564	3,125	3,189	3,287	3,088	2,719	3,241	3,534
Retail Generic	19,394	18,115	17,751	17,630	19,950	16,006	16,724	15,856
Retail90 Brand	883	916	914	917	951	948	967	942
Retail90 Generic	6,260	6,416	6,594	6,565	7,190	7,025	7,196	7,191
Mail Brand	29	36	40	38	42	30	38	35
Mail Generic	185	196	161	184	175	204	184	178
Specialty	420	476	486	485	495	520	491	507



Quarterly Key Pharmacy Benefit Metrics

Specialty Plan Cost

Category	Q1 2019	Q2 2019	Q3 2019	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020
Specialty Plan Cost	\$1,360,194	\$1,507,365	\$1,454,017	\$1,411,065	\$1,524,399	\$1,572,007	\$1,471,204	\$1,559,440
Total Plan Cost	\$4,499,486	\$4,530,265	\$4,428,298	\$4,472,131	\$4,893,192	\$4,763,678	\$4,761,468	\$4,769,527
Specialty Plan Cost %	30.23%	33.27%	32.83%	31.55%	31.15%	33.00%	30.90%	32.70%




- Specialty plan cost represents 32.70% of the SJVIA plan cost in Q4 2020
- Specialty claims volume increased in Q4 vs Q3 of 2020.
- SJVIA's specialty plan cost in Q4 was roughly 2-5% lower than the national average range (35% - 38%)

Quarterly Key Pharmacy Benefit Metrics

Generic Dispensing Rate


Category	Q1 2019	Q2 2019	Q3 2019	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020
Retail GDR	84.48%	85.29%	84.77%	84.29%	86.60%	85.48%	83.77%	81.77%
Retail90 GDR	87.64%	87.51%	87.83%	87.74%	88.32%	88.11%	88.15%	88.42%
Mail GDR	86.45%	84.48%	80.10%	82.88%	80.65%	87.18%	82.88%	83.57%



Quarterly Key Pharmacy Benefit Metrics

Retail vs Mail Service Cost Trend

Category	Q1 2019	Q2 2019	Q3 2019	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020
Retail Plan Cost	\$3,089,606	\$2,962,752	\$2,916,326	\$3,009,806	\$3,318,620	\$3,153,231	\$3,239,486	\$3,167,162
Mail Plan Cost	\$49,686	\$60,149	\$57,955	\$51,260	\$50,172	\$38,441	\$50,778	\$42,925
Retail Plan Cost %	98.42%	98.01%	98.05%	98.33%	98.51%	98.80%	98.46%	98.66%
Mail Plan Cost %	1.58%	1.99%	1.95%	1.67%	1.49%	1.20%	1.54%	1.34%



Quarterly Key Pharmacy Benefit Metrics

Top Drugs By Cost: SJVIA

Top Drugs By Ingredient Cost

Based on Paid Date: 01/01/2020-12/31/2020

Drug Label Name	Drug Group	Brand Generic Indicator	Formulary Tier	Speciality Indicator	Claim Count	Utilizers	Ingredient Cost	Days Supply	ICST per Rx	ICST per Day
HUMIRA PEN	ANALGESICS - ANTI-INFLAMMATORY	B	2	Y	133	17	\$928,313.24	3,724	\$6,979.80	\$249.28
TRULICITY	ANTIDIABETICS	B	2	N	605	108	\$721,785.44	25,718	\$1,193.03	\$28.07
JANUVIA	ANTIDIABETICS	B	2	N	443	107	\$414,040.47	26,894	\$934.63	\$15.40
JARDIANCE	ANTIDIABETICS	B	2	N	369	89	\$368,209.49	21,660	\$997.86	\$17.00
OZEMPIC	ANTIDIABETICS	B	2	N	295	61	\$360,334.00	12,800	\$1,221.47	\$28.15
SPRYCEL	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	B	2	Y	24	2	\$346,799.28	720	\$14,449.97	\$481.67
ENBREL SURECLICK	ANALGESICS - ANTI-INFLAMMATORY	B	2	Y	59	7	\$346,123.69	1,652	\$5,866.50	\$209.52
TRIKAFTA	RESPIRATORY AGENTS - MISC.	B	2	Y	13	1	\$324,318.28	364	\$24,947.56	\$890.98
COSENTYX SENSOREADY PEN	DERMATOLOGICALS	B	2	Y	47	8	\$312,404.01	1,316	\$6,646.89	\$237.39
FARXIGA	ANTIDIABETICS	B	2	N	315	75	\$297,634.02	17,819	\$944.87	\$16.70
DUPIXENT	DERMATOLOGICALS	B	2	Y	92	13	\$285,820.48	2,506	\$3,106.74	\$114.05
LATUDA	ANTIPSYCHOTICS/ANTIMANIC AGENTS	B	2	N	164	30	\$281,146.55	6,022	\$1,714.31	\$46.69
XELJANZ XR	ANALGESICS - ANTI-INFLAMMATORY	B	2	Y	52	8	\$243,657.37	1,560	\$4,685.72	\$156.19
TREMFYA	DERMATOLOGICALS	B	2	Y	20	4	\$226,936.82	1,092	\$11,346.84	\$207.82
ELIQUIS	ANTICOAGULANTS	B	2	N	312	71	\$221,004.34	14,493	\$708.35	\$15.25
HUMALOG	ANTIDIABETICS	B	2	N	155	39	\$209,776.17	7,382	\$1,353.39	\$28.42
LANTUS SOLOSTAR	ANTIDIABETICS	B	2	N	340	86	\$204,035.24	16,471	\$600.10	\$12.39
WIXELA INHUB	ANTIASTHMATIC AND BRONCHODILATOR AGENTS	G	1	N	379	148	\$197,738.85	17,070	\$521.74	\$11.58
STELARA	DERMATOLOGICALS	B	2	Y	8	2	\$185,032.06	616	\$23,129.01	\$300.38
HUMALOG KWIKPEN	ANTIDIABETICS	B	2	N	189	55	\$179,313.06	8,423	\$948.75	\$21.29
TRINTELLIX	ANTIDEPRESSANTS	B	3	N	304	64	\$174,791.19	12,764	\$574.97	\$13.69
HUMATROPE	ENDOCRINE AND METABOLIC AGENTS - MISC.	B	2	Y	49	4	\$172,867.12	1,440	\$3,527.90	\$120.05
CREON	DIGESTIVE AIDS	B	2	N	47	13	\$170,210.26	1,461	\$3,621.49	\$116.50
VASCEPA	ANTIHYPERTENSIVES	B	2	N	253	90	\$166,024.88	16,218	\$656.22	\$10.24
OTEZLA	ANALGESICS - ANTI-INFLAMMATORY	B	2	Y	45	5	\$160,786.49	1,350	\$3,573.03	\$119.10

Quarterly Key Pharmacy Benefit Metrics

Top Drugs By Claim Count: SJVIA

Top Drugs By Claim Count

Based on Paid Date: 01/01/2020-12/31/2020

Drug Label Name	Drug Group	Brand Generic Indicator	Formulary Tier	Speciality Indicator	Claim Count	Utilizers	Ingredient Cost	Days Supply	ICST per Rx	ICST per Day
ATORVASTATIN CALCIUM	ANTIHYPERTENSIVES	G	1	N	3,023	875	\$99,576.86	213,483	\$32.94	\$0.47
LISINAPRIL	ANTIHYPERTENSIVES	G	1	N	2,695	719	\$29,653.10	180,941	\$11.00	\$0.16
LEVOTHYROXINE SODIUM	THYROID AGENTS	G	1	N	2,606	608	\$67,822.12	176,586	\$26.03	\$0.38
ALBUTEROL SULFATE HFA	ANTIASTHMATIC AND BRONCHODILATOR AGENTS	G	1	N	2,440	1355	\$127,903.54	58,145	\$52.42	\$2.20
METFORMIN HYDROCHLORIDE	ANTIDIABETICS	G	1	N	1,999	574	\$40,085.57	127,754	\$20.05	\$0.31
HYDROCODONE/ACETAMINOPHEN	ANALGESICS - OPIOID	G	1	N	1,922	737	\$89,349.61	37,590	\$46.49	\$2.38
OMEPRAZOLE	ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS	G	1	N	1,756	605	\$39,787.03	104,544	\$22.66	\$0.38
AMLODIPINE BESYLATE	CALCIUM CHANNEL BLOCKERS	G	1	N	1,636	435	\$21,152.48	105,013	\$12.93	\$0.20
IBUPROFEN	ANALGESICS - ANTI-INFLAMMATORY	G	1	N	1,570	1123	\$37,367.27	30,735	\$23.80	\$1.22
BUPROPION HYDROCHLORIDE E	ANTIDEPRESSANTS	G	1	N	1,535	330	\$116,371.27	74,278	\$75.81	\$1.57
GABAPENTIN	ANTICONVULSANTS	G	1	N	1,455	437	\$57,393.98	61,220	\$39.45	\$0.94
LOSARTAN POTASSIUM	ANTIHYPERTENSIVES	G	1	N	1,422	395	\$49,183.07	94,822	\$34.59	\$0.52
METOPROLOL SUCCINATE ER	BETA BLOCKERS	G	1	N	1,323	329	\$68,379.94	89,095	\$51.69	\$0.77
MONTELUKAST SODIUM	ANTIASTHMATIC AND BRONCHODILATOR AGENTS	G	1	N	1,215	444	\$31,198.51	65,947	\$25.68	\$0.47
HYDROCHLOROTHIAZIDE	DIURETICS	G	1	N	1,211	345	\$12,151.56	79,352	\$10.03	\$0.15
AZITHROMYCIN	MACROLIDES	G	1	N	1,206	1010	\$25,512.70	7,627	\$21.15	\$3.35
ALPRAZOLAM	ANTI-ANXIETY AGENTS	G	1	N	1,148	326	\$11,749.85	30,100	\$10.24	\$0.39
AMOXICILLIN	PENICILLINS	G	1	N	1,136	960	\$9,777.75	9,795	\$8.61	\$1.00
FLUTICASONE PROPIONATE	NASAL AGENTS - SYSTEMIC AND TOPICAL	G	1	N	1,114	645	\$39,100.00	46,019	\$35.10	\$0.85
ESCITALOPRAM OXALATE	ANTIDEPRESSANTS	G	1	N	1,055	297	\$20,213.54	55,403	\$19.16	\$0.36
PREDNISONE	CORTICOSTEROIDS	G	1	N	1,021	693	\$8,071.72	15,289	\$7.91	\$0.53
ROSUVASTATIN CALCIUM	ANTIHYPERTENSIVES	G	1	N	1,002	280	\$37,235.54	67,604	\$37.16	\$0.55
VITAMIN D	VITAMINS	G	1	N	937	388	\$6,807.98	52,689	\$7.27	\$0.13
PANTOPRAZOLE SODIUM	ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS	G	1	N	901	295	\$21,742.73	55,898	\$24.13	\$0.39
AMOXICILLIN/CLAVULANATE P	PENICILLINS	G	1	N	868	738	\$33,295.19	8,506	\$38.36	\$3.91

Quarterly Key Pharmacy Benefit Metrics

Specialty Drug Oversight

- The management of specialty drugs is complex, as are the conditions that specialty drugs treat. With recent advances in drug therapies, patients with complex conditions now have better options to manage their conditions. While plan sponsors like the SJVIA recognize the value of these medications to their members and want to provide best-in-class drug benefits, the cost management of these drugs requires utilization management and benefit design strategies.
- Strategies implemented for the SJVIA include:
 - Prior authorization/clinical review
 - Specialty pharmacy channel management
 - Ongoing formulary review for the most cost and clinically effective medications
 - Manufacturer assistance when available

Quarterly Key Pharmacy Benefit Metrics

Rebates & Clinical Management Savings

- Rebates:
 - Q1 net rebate amount is \$546,922 total
 - Q2 net rebate amount is \$578,620
 - Q3 **estimated** net rebate amount is \$751,762

*Beginning with the fourth quarter of 2020, Rebates will be paid within 120 days at the end of the applicable quarter.

- Clinical Management-
 - Clinical Guarantee (Q1-Q2)- \$370,00
 - Clinical Savings Performance (Q1-Q2)- \$2,102,574

*Keenan performs a clinical savings financial audit and presents the final report to the SJVIA upon completion of the end of the plan year.

Appendix

Quarterly Key Pharmacy Benefit Metrics

SJVIA Cost Trend by Quarter (Tulare)

Category	Q1 2019	Q2 2019	Q3 2019	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020
Gross Cost	\$2,073,104	\$2,107,473	\$2,152,107	\$2,020,551	\$2,150,586	\$2,111,798	\$2,103,411	\$2,126,190
Plan Cost	\$1,899,589	\$1,940,873	\$1,988,521	\$1,859,979	\$1,968,537	\$1,939,264	\$1,929,831	\$1,954,639
Member Cost	\$173,515	\$166,600	\$163,586	\$160,572	\$182,049	\$172,533	\$173,579	\$171,551



This report details the total member and plan costs, by quarter, for the most recent 8 quarter period
 These represent total dollars spent for all products, including specialty drugs

Quarterly Key Pharmacy Benefit Metrics

SJVIA Cost Trend by Quarter (Fresno)

Category	Q1 2019	Q2 2019	Q3 2019	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020
Gross Cost	\$2,808,470	\$2,776,980	\$2,631,512	\$2,809,426	\$3,166,647	\$3,041,764	\$3,042,464	\$3,023,845
Plan Cost	\$2,583,550	\$2,572,415	\$2,430,504	\$2,600,251	\$2,922,097	\$2,824,414	\$2,831,636	\$2,814,888
Member Cost	\$224,920	\$204,566	\$201,008	\$209,175	\$244,550	\$217,350	\$210,828	\$208,956




This report details the total member and plan costs, by quarter, for the most recent 8 quarter period
 These represent total dollars spent for all products, including specialty drugs

Quarterly Key Pharmacy Benefit Metrics

Plan Cost by Channel (Tulare)


Category	Q1 2019	Q2 2019	Q3 2019	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020
Retail Brand	\$540,200	\$481,867	\$490,293	\$444,835	\$473,482	\$471,239	\$485,916	\$500,819
Retail Generic	\$257,950	\$209,942	\$221,043	\$264,207	\$292,110	\$264,094	\$250,354	\$225,339
Retail90 Brand	\$267,773	\$294,975	\$293,744	\$321,262	\$335,014	\$343,733	\$343,469	\$347,451
Retail90 Generic	\$153,688	\$140,148	\$131,689	\$135,880	\$141,460	\$154,534	\$178,844	\$174,057
Mail Brand	\$21,701	\$27,366	\$19,654	\$19,733	\$21,121	\$16,314	\$20,701	\$19,965
Mail Generic	\$14,646	\$13,117	\$12,358	\$11,265	\$9,610	\$8,881	\$13,234	\$13,230
Specialty	\$643,631	\$773,458	\$819,740	\$662,797	\$695,741	\$680,470	\$637,313	\$673,779



Quarterly Key Pharmacy Benefit Metrics

Plan Cost by Channel (Fresno)


Category	Q1 2019	Q2 2019	Q3 2019	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020
Retail Brand	\$768,422	\$731,735	\$710,910	\$717,177	\$777,547	\$715,434	\$718,758	\$713,086
Retail Generic	\$360,811	\$341,658	\$327,897	\$404,658	\$474,932	\$411,102	\$410,811	\$343,292
Retail90 Brand	\$479,922	\$522,761	\$488,671	\$495,475	\$566,030	\$542,467	\$571,612	\$581,409
Retail90 Generic	\$253,036	\$233,246	\$245,248	\$218,620	\$255,489	\$250,628	\$279,722	\$281,710
Mail Brand	\$6,303	\$12,634	\$21,319	\$15,952	\$14,257	\$6,313	\$11,404	\$2,857
Mail Generic	\$6,996	\$6,912	\$4,592	\$4,192	\$5,185	\$6,933	\$5,438	\$6,874
Specialty	\$708,060	\$723,469	\$631,867	\$744,176	\$828,659	\$891,537	\$833,891	\$885,661



Quarterly Key Pharmacy Benefit Metrics

Total Claims Volume by Channel (Tulare)


Category	Q1 2019	Q2 2019	Q3 2019	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020
Retail Brand	1,421	1,239	1,257	1,284	1,207	1,111	1,290	1,367
Retail Generic	8,497	7,915	7,823	7,788	8,740	7,108	7,440	7,312
Retail90 Brand	319	326	336	346	343	358	358	343
Retail90 Generic	2,441	2,507	2,614	2,570	2,753	2,854	2,905	2,876
Mail Brand	21	22	21	23	22	18	22	26
Mail Generic	130	132	110	128	120	121	130	124
Specialty	185	211	203	198	198	200	188	197



Quarterly Key Pharmacy Benefit Metrics

Total Claims Volume by Channel (Fresno)


Category	Q1 2019	Q2 2019	Q3 2019	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020
Retail Brand	2,133	1,877	1,924	1,995	1,879	1,608	1,951	2,167
Retail Generic	10,750	10,070	9,832	9,738	11,178	8,898	9,284	8,544
Retail90 Brand	560	586	574	565	607	590	609	599
Retail90 Generic	3,783	3,871	3,939	3,955	4,425	4,171	4,291	4,315
Mail Brand	8	14	19	15	20	12	16	9
Mail Generic	53	61	49	53	55	83	54	54
Specialty	226	258	276	281	297	320	303	310



Quarterly Key Pharmacy Benefit Metrics

Specialty Plan Cost (Tulare)


Category	Q1 2019	Q2 2019	Q3 2019	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020
Specialty Plan Cost	\$643,631	\$773,458	\$819,740	\$662,797	\$695,741	\$680,470	\$637,313	\$673,779
Total Plan Cost	\$1,899,589	\$1,940,873	\$1,988,521	\$1,859,979	\$1,968,537	\$1,939,264	\$1,929,831	\$1,954,639
Specialty Plan Cost %	33.88%	39.85%	41.22%	35.63%	35.34%	35.09%	33.02%	34.47%



Quarterly Key Pharmacy Benefit Metrics

Specialty Plan Cost (Fresno)


Category	Q1 2019	Q2 2019	Q3 2019	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020
Specialty Plan Cost	\$708,060	\$723,469	\$631,867	\$744,176	\$828,659	\$891,537	\$833,891	\$885,661
Total Plan Cost	\$2,583,550	\$2,572,415	\$2,430,504	\$2,600,251	\$2,922,097	\$2,824,414	\$2,831,636	\$2,814,888
Specialty Plan Cost %	27.41%	28.12%	26.00%	28.62%	28.36%	31.57%	29.45%	31.46%



Quarterly Key Pharmacy Benefit Metrics

Generic Dispensing Rate (Tulare)

Category	Q1 2019	Q2 2019	Q3 2019	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020
Retail GDR	85.67%	86.46%	86.16%	85.85%	87.87%	86.48%	85.22%	84.25%
Retail90 GDR	88.44%	88.49%	88.61%	88.13%	88.92%	88.85%	89.03%	89.34%
Mail GDR	86.09%	85.71%	83.97%	84.77%	84.51%	87.05%	85.53%	82.67%




Excludes Specialty

Quarterly Key Pharmacy Benefit Metrics

Generic Dispensing Rate (Fresno)

Category	Q1 2019	Q2 2019	Q3 2019	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020
Retail GDR	83.44%	84.29%	83.63%	83.00%	85.61%	84.69%	82.63%	79.77%
Retail90 GDR	87.11%	86.85%	87.28%	87.50%	87.94%	87.61%	87.57%	87.81%
Mail GDR	86.89%	81.33%	72.06%	77.94%	73.33%	87.37%	77.14%	85.71%




Excludes Specialty

Quarterly Key Pharmacy Benefit Metrics

Generic Dispensing Rate (Marysville)

Category	Q1 2019	Q2 2019	Q3 2019	Q4 2019	Q1 2020
Retail GDR	93.63%	93.53%	92.31%	92.86%	94.12%
Retail90 GDR	90.00%	90.48%	91.11%	86.96%	92.31%
Mail GDR	100.00%	100.00%	100.00%	100.00%	0.00%




Excludes Specialty

Quarterly Key Pharmacy Benefit Metrics

Retail vs Mail Service Cost Trend (Tulare)

Category	Q1 2019	Q2 2019	Q3 2019	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020
Retail Plan Cost	\$1,219,611	\$1,126,932	\$1,136,770	\$1,166,184	\$1,242,066	\$1,233,600	\$1,258,583	\$1,247,666
Mail Plan Cost	\$36,347	\$40,482	\$32,011	\$30,998	\$30,731	\$25,195	\$33,935	\$33,194
Retail Plan Cost %	97.11%	96.53%	97.26%	97.41%	97.59%	98.00%	97.37%	97.41%
Mail Plan Cost %	2.89%	3.47%	2.74%	2.59%	2.41%	2.00%	2.63%	2.59%




Excludes Specialty

Quarterly Key Pharmacy Benefit Metrics

Retail vs Mail Service Cost Trend (Fresno)

Category	Q1 2019	Q2 2019	Q3 2019	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020
Retail Plan Cost	\$1,862,191	\$1,829,400	\$1,772,727	\$1,835,931	\$2,073,997	\$1,919,630	\$1,980,903	\$1,919,496
Mail Plan Cost	\$13,299	\$19,546	\$25,911	\$20,144	\$19,442	\$13,246	\$16,842	\$9,731
Retail Plan Cost %	99.29%	98.94%	98.56%	98.91%	99.07%	99.31%	99.16%	99.50%
Mail Plan Cost %	0.71%	1.06%	1.44%	1.09%	0.93%	0.69%	0.84%	0.50%





Excludes Specialty

Quarterly Key Pharmacy Benefit Metrics

Retail vs Mail Service Cost Trend (Marysville)

Category	Q1 2019	Q2 2019	Q3 2019	Q4 2019	Q1 2020
Retail Plan Cost	\$7,804	\$6,420	\$6,830	\$7,691	\$2,557
Mail Plan Cost	\$40	\$121	\$33	\$119	\$0
Retail Plan Cost %	99.49%	98.15%	99.52%	98.48%	100.00%
Mail Plan Cost %	0.51%	1.85%	0.48%	1.52%	0.00%



Excludes Specialty

Quarterly Key Pharmacy Benefit Metrics

Top Drugs By Cost: Tulare

Top Drugs By Ingredient Cost: Tulare
Based on Paid Date: 01/01/2020-12/31/2020

Drug Label Name	Drug Group	Brand Generic Indicator	Formulary Tier	Speciality Indicator	Claim Count	Utilizers	Ingredient Cost	Days Supply	ICST per Rx	ICST per Day
HUMIRA PEN	ANALGESICS - ANTI-INFLAMMATORY	B	2	Y	67	10	\$451,029.45	1,876	\$6,731.78	\$240.42
TRIKAFTA	RESPIRATORY AGENTS - MISC.	B	2	Y	13	1	\$324,318.28	364	\$24,947.56	\$890.98
TRULICITY	ANTIDIABETICS	B	2	N	200	40	\$256,634.37	9,168	\$1,283.17	\$27.99
XELJANZ XR	ANALGESICS - ANTI-INFLAMMATORY	B	2	Y	44	7	\$206,206.33	1,320	\$4,686.51	\$156.22
OZEMPIC	ANTIDIABETICS	B	2	N	158	25	\$182,125.69	6,415	\$1,152.69	\$28.39
SPRYCEL	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	B	2	Y	12	1	\$173,399.64	360	\$14,449.97	\$481.67
JANUVIA	ANTIDIABETICS	B	2	N	204	43	\$172,038.48	11,144	\$843.33	\$15.44
JARDIANCE	ANTIDIABETICS	B	2	N	178	36	\$157,602.04	9,210	\$885.40	\$17.11
ELIQUIS	ANTICOAGULANTS	B	2	N	202	41	\$146,596.75	9,737	\$725.73	\$15.06
FARXIGA	ANTIDIABETICS	B	2	N	163	31	\$129,951.84	7,710	\$797.25	\$16.85
CREON	DIGESTIVE AIDS	B	2	N	25	5	\$125,792.54	709	\$5,031.70	\$177.42
TRINTELLIX	ANTIDEPRESSANTS	B	3	N	204	41	\$113,365.52	8,324	\$555.71	\$13.62
TECFIDERA	PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS - MISC.	B	2	Y	13	3	\$112,320.39	390	\$8,640.03	\$288.00
XTANDI	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	B	2	Y	9	1	\$111,597.22	270	\$12,399.69	\$413.32
XARELTO	ANTICOAGULANTS	B	2	N	132	29	\$109,612.59	7,000	\$830.40	\$15.66
ZYTIGA	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	B	2	Y	9	1	\$102,294.45	270	\$11,366.05	\$378.87
ABIRATERONE ACETATE	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	G	1	Y	20	3	\$95,857.80	600	\$4,792.89	\$159.76
STELARA	DERMATOLOGICALS	B	2	Y	4	1	\$91,962.04	336	\$22,990.51	\$273.70
LANTUS SOLOSTAR	ANTIDIABETICS	B	2	N	158	34	\$84,409.88	7,246	\$534.24	\$11.65
ARIKAYCE	AMINOGLYCOSIDES	B	2	N	7	1	\$83,009.57	196	\$11,858.51	\$423.52
PREVYMIS	ANTIVIRALS	B	2	Y	13	1	\$77,939.68	364	\$5,995.36	\$214.12
ENBREL SURECLICK	ANALGESICS - ANTI-INFLAMMATORY	B	2	Y	14	2	\$77,371.33	392	\$5,526.52	\$197.38
HUMALOG	ANTIDIABETICS	B	2	N	71	18	\$76,815.78	3,135	\$1,081.91	\$24.50
LYNPARZA	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	B	2	Y	5	1	\$73,944.35	150	\$14,788.87	\$492.96
NUTROPIN AQ NUSPIN 10	ENDOCRINE AND METABOLIC AGENTS - MISC.	B	3	Y	12	1	\$69,571.69	348	\$5,797.64	\$199.92

Quarterly Key Pharmacy Benefit Metrics

Top Drugs By Claim Count: Tulare

Top Drugs By Claim Count: Tulare

Based on Paid Date: 01/01/2020-12/31/2020

Drug Label Name	Drug Group	Brand Generic Indicator	Formulary Tier	Speciality Indicator	Claim Count	Utilizers	Ingredient Cost	Days Supply	ICST per Rx	ICST per Day
ATORVASTATIN CALCIUM	ANTIHYPERTENSIVES	G	1	N	1,230	324	\$38,254.38	80,026	\$31.10	\$0.48
LEVOTHYROXINE SODIUM	THYROID AGENTS	G	1	N	1,199	259	\$28,732.84	72,799	\$23.96	\$0.39
LISINAPRIL	ANTIHYPERTENSIVES	G	1	N	1,160	295	\$12,102.41	73,139	\$10.43	\$0.17
ALBUTEROL SULFATE HFA	ANTIASTHMATIC AND BRONCHODILATOR AGENTS	G	1	N	794	450	\$41,554.70	18,081	\$52.34	\$2.30
OMEPRAZOLE	ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS	G	1	N	776	240	\$16,820.21	43,451	\$21.68	\$0.39
HYDROCODONE/ACETAMINOPHEN	ANALGESICS - OPIOID	G	1	N	762	292	\$37,484.61	15,637	\$49.19	\$2.40
AMLODIPINE BESYLATE	CALCIUM CHANNEL BLOCKERS	G	1	N	726	185	\$9,127.39	43,786	\$12.57	\$0.21
METFORMIN HYDROCHLORIDE	ANTIDIABETICS	G	1	N	719	217	\$14,335.17	45,658	\$19.94	\$0.31
LOSARTAN POTASSIUM	ANTIHYPERTENSIVES	G	1	N	694	180	\$22,986.26	42,591	\$33.12	\$0.54
BUPROPION HYDROCHLORIDE E	ANTIDEPRESSANTS	G	1	N	686	143	\$45,392.59	31,603	\$66.17	\$1.44
MONTELUKAST SODIUM	ANTIASTHMATIC AND BRONCHODILATOR AGENTS	G	1	N	655	233	\$16,378.37	34,363	\$25.01	\$0.48
GABAPENTIN	ANTICONVULSANTS	G	1	N	641	175	\$23,637.35	26,369	\$36.88	\$0.90
ALPRAZOLAM	ANTI-ANXIETY AGENTS	G	1	N	612	186	\$6,294.75	16,379	\$10.29	\$0.38
HYDROCHLOROTHIAZIDE	DIURETICS	G	1	N	611	159	\$6,462.18	37,368	\$10.58	\$0.17
METOPROLOL SUCCINATE ER	BETA BLOCKERS	G	1	N	606	137	\$29,565.79	39,108	\$48.79	\$0.76
IBUPROFEN	ANALGESICS - ANTI-INFLAMMATORY	G	1	N	576	437	\$12,793.58	10,306	\$22.21	\$1.24
ESCITALOPRAM OXALATE	ANTIDEPRESSANTS	G	1	N	514	138	\$9,318.95	24,772	\$18.13	\$0.38
AZITHROMYCIN	MACROLIDES	G	1	N	494	400	\$11,687.78	3,487	\$23.66	\$3.35
ROSUVASTATIN CALCIUM	ANTIHYPERTENSIVES	G	1	N	480	119	\$16,258.94	29,570	\$33.87	\$0.55
PANTOPRAZOLE SODIUM	ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS	G	1	N	465	141	\$10,473.60	27,122	\$22.52	\$0.39
AMOXICILLIN	PENICILLINS	G	1	N	457	388	\$3,802.72	3,719	\$8.32	\$1.02
PREDNISONE	CORTICOSTEROIDS	G	1	N	453	291	\$4,440.29	8,179	\$9.80	\$0.54
SERTRALINE HCL	ANTIDEPRESSANTS	G	1	N	409	117	\$5,939.81	19,391	\$14.52	\$0.31
FLUTICASONE PROPIONATE	NASAL AGENTS - SYSTEMIC AND TOPICAL	G	1	N	392	229	\$14,117.09	16,349	\$36.01	\$0.86
VITAMIN D	VITAMINS	G	1	N	389	155	\$2,834.96	19,072	\$7.29	\$0.15

Quarterly Key Pharmacy Benefit Metrics

Top Drugs By Cost: Fresno

Top Drugs By Ingredient Cost: Fresno

Based on Paid Date: 01/01/2020-12/31/2020

Drug Label Name	Drug Group	Brand Generic Indicator	Formulary Tier	Speciality Indicator	Claim Count	Utilizers	Ingredient Cost	Days Supply	ICST per Rx	ICST per Day
HUMIRA PEN	ANALGESICS - ANTI-INFLAMMATORY	B	2	Y	66	7	\$477,283.79	1,848	\$7,231.57	\$258.27
TRULICITY	ANTIDIABETICS	B	2	N	405	68	\$465,151.07	16,550	\$1,148.52	\$28.11
COSENTYX SENSOREADY PEN	DERMATOLOGICALS	B	2	Y	41	6	\$271,907.20	1,148	\$6,631.88	\$236.85
ENBREL SURECLICK	ANALGESICS - ANTI-INFLAMMATORY	B	2	Y	45	5	\$268,752.36	1,260	\$5,972.27	\$213.30
DUPIXENT	DERMATOLOGICALS	B	2	Y	82	11	\$254,694.69	2,240	\$3,106.03	\$113.70
LATUDA	ANTIPSYCHOTICS/ANTIMANIC AGENTS	B	2	N	141	23	\$251,037.94	5,332	\$1,780.41	\$47.08
JANUVIA	ANTIDIABETICS	B	2	N	239	64	\$242,001.99	15,750	\$1,012.56	\$15.37
JARDIANCE	ANTIDIABETICS	B	2	N	191	53	\$210,607.45	12,450	\$1,102.66	\$16.92
OZEMPIC	ANTIDIABETICS	B	2	N	137	36	\$178,208.31	6,385	\$1,300.79	\$27.91
SPRYCEL	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	B	2	Y	12	1	\$173,399.64	360	\$14,449.97	\$481.67
TREMFYA	DERMATOLOGICALS	B	2	Y	15	3	\$170,736.80	812	\$11,382.45	\$210.27
FARXIGA	ANTIDIABETICS	B	2	N	152	44	\$167,682.18	10,109	\$1,103.17	\$16.59
HUMATROPE	ENDOCRINE AND METABOLIC AGENTS - MISC.	B	2	Y	38	3	\$164,097.88	1,110	\$4,318.37	\$147.84
BIKTARVY	ANTIVIRALS	B	2	Y	45	4	\$148,094.37	1,350	\$3,290.99	\$109.70
CIMZIA	GASTROINTESTINAL AGENTS - MISC.	B	3	Y	27	3	\$148,023.07	756	\$5,482.34	\$195.80
WIXELA INHUB	ANTIASTHMATIC AND BRONCHODILATOR AGENTS	G	1	N	268	96	\$142,220.13	12,300	\$530.67	\$11.56
VASCEPA	ANTHYPERLIPIDEMICS	B	2	N	199	73	\$139,458.48	13,640	\$700.80	\$10.22
HUMALOG	ANTIDIABETICS	B	2	N	84	21	\$132,960.39	4,247	\$1,582.86	\$31.31
LANTUS SOLOSTAR	ANTIDIABETICS	B	2	N	182	52	\$119,625.36	9,225	\$657.28	\$12.97
GENOTROPIN	ENDOCRINE AND METABOLIC AGENTS - MISC.	B	2	Y	24	2	\$119,247.76	672	\$4,968.66	\$177.45
HUMALOG KWIKPEN	ANTIDIABETICS	B	2	N	114	36	\$117,067.56	5,542	\$1,026.91	\$21.12
OTEZLA	ANALGESICS - ANTI-INFLAMMATORY	B	2	Y	30	3	\$107,126.69	900	\$3,570.89	\$119.03
INVOKANA	ANTIDIABETICS	B	2	N	110	24	\$100,181.95	5,934	\$910.75	\$16.88
REXULTI	ANTIPSYCHOTICS/ANTIMANIC AGENTS	B	3	N	65	13	\$96,732.65	2,490	\$1,488.19	\$38.85
BUDESONIDE/FORMOTEROL FUM	ANTIASTHMATIC AND BRONCHODILATOR AGENTS	G	1	N	271	114	\$93,530.42	9,837	\$345.13	\$9.51

Quarterly Key Pharmacy Benefit Metrics

Top Drugs By Claim Count: Fresno

Top Drugs By Claim Count: Fresno

Based on Paid Date: 01/01/2020-12/31/2020

Drug Label Name	Drug Group	Brand Generic Indicator	Formulary Tier	Speciality Indicator	Claim Count	Utilizers	Ingredient Cost	Days Supply	ICST per Rx	ICST per Day
ATORVASTATIN CALCIUM	ANTIHYPERTENSIVES	G	1	N	1,793	550	\$61,322.48	133,457	\$34.20	\$0.46
ALBUTEROL SULFATE HFA	ANTIASTHMATIC AND BRONCHODILATOR AGENTS	G	1	N	1,646	905	\$86,348.84	40,064	\$52.46	\$2.16
LISINAPRIL	ANTIHYPERTENSIVES	G	1	N	1,535	424	\$17,550.69	107,802	\$11.43	\$0.16
LEVOTHYROXINE SODIUM	THYROID AGENTS	G	1	N	1,406	348	\$39,062.39	103,697	\$27.78	\$0.38
METFORMIN HYDROCHLORIDE	ANTIDIABETICS	G	1	N	1,280	357	\$25,750.40	82,096	\$20.12	\$0.31
HYDROCODONE/ACETAMINOPHEN	ANALGESICS - OPIOID	G	1	N	1,160	445	\$51,865.00	21,953	\$44.71	\$2.36
IBUPROFEN	ANALGESICS - ANTI-INFLAMMATORY	G	1	N	991	682	\$24,544.13	20,387	\$24.77	\$1.20
OMEPRAZOLE	ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS	G	1	N	978	363	\$22,914.24	60,913	\$23.43	\$0.38
AMLODIPINE BESYLATE	CALCIUM CHANNEL BLOCKERS	G	1	N	909	249	\$12,000.07	61,137	\$13.20	\$0.20
BUPROPION HYDROCHLORIDE E	ANTIDEPRESSANTS	G	1	N	849	187	\$70,978.68	42,675	\$83.60	\$1.66
GABAPENTIN	ANTICONVULSANTS	G	1	N	814	262	\$33,756.63	34,851	\$41.47	\$0.97
LOSARTAN POTASSIUM	ANTIHYPERTENSIVES	G	1	N	728	215	\$26,196.81	52,231	\$35.98	\$0.50
FLUTICASONE PROPIONATE	NASAL AGENTS - SYSTEMIC AND TOPICAL	G	1	N	722	415	\$24,982.91	29,670	\$34.60	\$0.84
METOPROLOL SUCCINATE ER	BETA BLOCKERS	G	1	N	717	192	\$38,814.15	49,987	\$54.13	\$0.78
AZITHROMYCIN	MACROLIDES	G	1	N	711	608	\$13,818.30	4,139	\$19.44	\$3.34
AMOXICILLIN	PENICILLINS	G	1	N	676	569	\$5,957.76	6,049	\$8.81	\$0.98
HYDROCHLOROTHIAZIDE	DIURETICS	G	1	N	600	186	\$5,689.38	41,984	\$9.48	\$0.14
PREDNISONE	CORTICOSTEROIDS	G	1	N	567	401	\$3,629.38	7,105	\$6.40	\$0.51
MONTELUKAST SODIUM	ANTIASTHMATIC AND BRONCHODILATOR AGENTS	G	1	N	559	210	\$14,807.96	31,554	\$26.49	\$0.47
VITAMIN D	VITAMINS	G	1	N	548	233	\$3,973.02	33,617	\$7.25	\$0.12
ESCITALOPRAM OXALATE	ANTIDEPRESSANTS	G	1	N	541	159	\$10,894.59	30,631	\$20.14	\$0.36
ALPRAZOLAM	ANTI-ANXIETY AGENTS	G	1	N	535	139	\$5,451.56	13,691	\$10.19	\$0.40
ROSUVASTATIN CALCIUM	ANTIHYPERTENSIVES	G	1	N	522	161	\$20,976.60	38,034	\$40.19	\$0.55
AMOXICILLIN/CLAVULANATE P	PENICILLINS	G	1	N	487	427	\$19,240.90	4,894	\$39.51	\$3.93
PANTOPRAZOLE SODIUM	ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS	G	1	N	436	154	\$11,269.13	28,776	\$25.85	\$0.39

Quarterly Key Pharmacy Benefit Metrics

Top Drugs By Cost: Marysville

Top Drugs By Ingredient Cost: Marysville
Based on Paid Date: 01/01/2020-12/31/2020

Drug Label Name	Drug Group	Brand Generic Indicator	Formulary Tier	Speciality Indicator	Claim Count	Utilizers	Ingredient Cost	Days Supply	ICST per Rx	ICST per Day
JUBLIA	DERMATOLOGICALS	B	3	N	1	1	\$1,238.67	30	1238.67	41.289
IVERMECTIN	DERMATOLOGICALS	G	1	N	1	1	\$523.76	20	523.76	26.188
BICILLIN L-A	PENICILLINS	B	2	N	1	1	\$359.84	4	359.84	89.96
LEVETIRACETAM ER	ANTICONVULSANTS	G	1	N	1	1	\$167.99	90	167.99	1.866555556
NORLYDA	CONTRACEPTIVES	G	1	N	1	1	\$72.74	84	72.74	0.865952381
TRI-LO-SPRINTEC	CONTRACEPTIVES	G	1	N	2	1	\$57.54	56	28.77	1.0275
OMEPRAZOLE	ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS	G	1	N	2	2	\$52.58	180	26.29	0.292111111
DROSPIRENONE/ETHINYL ESTR	CONTRACEPTIVES	G	1	N	1	1	\$48.06	28	48.06	1.716428571
OFLOXACIN	OPHTHALMIC AGENTS	G	1	N	1	1	\$37.04	17	37.04	2.178823529
AMOXICILLIN/CLAVULANATE P	PENICILLINS	G	1	N	1	1	\$34.51	10	34.51	3.451
OXYBUTYNIN CHLORIDE ER	URINARY ANTISPASMODICS	G	1	N	0	1	\$33.15	0	#DIV/0!	#DIV/0!
GUANFACINE HYDROCHLORIDE	ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS	G	1	N	1	1	\$32.60	30	32.6	1.086666667
IBUPROFEN	ANALGESICS - ANTI-INFLAMMATORY	G	1	N	3	4	\$29.56	42	9.853333333	0.703809524
LEVOTHYROXINE SODIUM	THYROID AGENTS	G	1	N	1	1	\$26.89	90	26.89	0.298777778
SERTRALINE HCL	ANTIDEPRESSANTS	G	1	N	3	2	\$26.20	150	8.733333333	0.174666667
ALLOPURINOL	GOUT AGENTS	G	1	N	1	1	\$25.99	90	25.99	0.288777778
AMLODIPINE BESYLATE	CALCIUM CHANNEL BLOCKERS	G	1	N	1	1	\$25.02	90	25.02	0.278
FUROSEMIDE	DIURETICS	G	1	N	1	1	\$24.69	90	24.69	0.274333333
VALACYCLOVIR HCL	ANTIVIRALS	G	1	N	1	1	\$23.32	5	23.32	4.664
TRAZODONE HYDROCHLORIDE	ANTIDEPRESSANTS	G	1	N	3	1	\$22.47	90	7.49	0.249666667
SPIRONOLACTONE	DIURETICS	G	1	N	1	1	\$20.34	90	20.34	0.226
VENLAFAXINE HCL ER	ANTIDEPRESSANTS	G	1	N	2	2	\$19.91	60	9.955	0.331833333
BENAZEPRIL HCL	ANTIHYPERTENSIVES	G	1	N	1	1	\$18.80	90	18.8	0.208888889
AMOXICILLIN	PENICILLINS	G	1	N	3	3	\$17.27	27	5.756666667	0.63962963
ACYCLOVIR	ANTIVIRALS	G	1	N	1	1	\$12.54	30	12.54	0.418

Quarterly Key Pharmacy Benefit Metrics

Top Drugs By Claim Count: Marysville

Top Drugs By Claim Count: Marysville
Based on Paid Date: 01/01/2020-12/31/2020

Drug Label Name	Drug Group	Brand Generic Indicator	Formulary Tier	Speciality Indicator	Claim Count	Utilizers	Ingredient Cost	Days Supply	ICST per Rx	ICST per Day
AMOXICILLIN	PENICILLINS	G	1	N	3	3	\$17.27	27	\$5.76	\$0.64
IBUPROFEN	ANALGESICS - ANTI-INFLAMMATORY	G	1	N	3	4	\$29.56	42	\$9.85	\$0.70
SERTRALINE HCL	ANTIDEPRESSANTS	G	1	N	3	2	\$26.20	150	\$8.73	\$0.17
TRAZODONE HYDROCHLORIDE	ANTIDEPRESSANTS	G	1	N	3	1	\$22.47	90	\$7.49	\$0.25
OMEPRAZOLE	ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS	G	1	N	2	2	\$52.58	180	\$26.29	\$0.29
TRI-LO-SPRITEC	CONTRACEPTIVES	G	1	N	2	1	\$57.54	56	\$28.77	\$1.03
VENLAFAXINE HCL ER	ANTIDEPRESSANTS	G	1	N	2	2	\$19.91	60	\$9.96	\$0.33
GUANFACINE HYDROCHLORIDE	ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS	G	1	N	1	1	\$32.60	30	\$32.60	\$1.09
FUROSEMIDE	DIURETICS	G	1	N	1	1	\$24.69	90	\$24.69	\$0.27
DROSPIRENONE/ETHINYL ESTR	CONTRACEPTIVES	G	1	N	1	1	\$48.06	28	\$48.06	\$1.72
CLONIDINE HCL	ANTIHYPERTENSIVES	G	1	N	1	1	\$6.00	30	\$6.00	\$0.20
AMLODIPINE BESYLATE	CALCIUM CHANNEL BLOCKERS	G	1	N	1	1	\$25.02	90	\$25.02	\$0.28
ALPRAZOLAM	ANTI-ANXIETY AGENTS	G	1	N	1	1	\$3.54	30	\$3.54	\$0.12
ALLOPURINOL	GOUT AGENTS	G	1	N	1	1	\$25.99	90	\$25.99	\$0.29
ACYCLOVIR	ANTIVIRALS	G	1	N	1	1	\$12.54	30	\$12.54	\$0.42
BENAZEPRIL HCL	ANTIHYPERTENSIVES	G	1	N	1	1	\$18.80	90	\$18.80	\$0.21
BD 1ML TUBERCULIN SYRINGE	MEDICAL DEVICES AND SUPPLIES	B	2	N	1	1	\$1.68	84	\$1.68	\$0.02
AZITHROMYCIN	MACROLIDES	G	1	N	1	2	\$6.62	1	\$6.62	\$6.62
LEVOTHYROXINE SODIUM	THYROID AGENTS	G	1	N	1	1	\$26.89	90	\$26.89	\$0.30
LEVETIRACETAM ER	ANTICONVULSANTS	G	1	N	1	1	\$167.99	90	\$167.99	\$1.87
JUBLIA	DERMATOLOGICALS	B	3	N	1	1	\$1,238.67	30	\$1,238.67	\$41.29
IVERMECTIN	DERMATOLOGICALS	G	1	N	1	1	\$523.76	20	\$523.76	\$26.19
AMOXICILLIN/CLAVULANATE P	PENICILLINS	G	1	N	1	1	\$34.51	10	\$34.51	\$3.45
BICILLIN L-A	PENICILLINS	B	2	N	1	1	\$359.84	4	\$359.84	\$89.96
LISINOPRIL/HYDROCHLOROTH	ANTIHYPERTENSIVES	G	1	N	1	1	\$8.71	90	\$8.71	\$0.10